A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)

drug protocol number
CYTB323J12201
drug sponsor
Rapcabtagene autoleucel (YTB323)
drug study
Rapcabtagene autoleucel (YTB323)
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase